- Home
- CLDI vs CLRB Comparison
CLDI vs CLRB Comparison
Compare CLDI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- CLRB
- Stock Information
- Founded
- CLDI 2014
- CLRB 2002
- Country
- CLDI United States
- CLRB United States
- Employees
- CLDI N/A
- CLRB N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- CLRB Health Care
- Exchange
- CLDI Nasdaq
- CLRB Nasdaq
- Market Cap
- CLDI 12.0M
- CLRB 12.5M
- IPO Year
- CLDI N/A
- CLRB N/A
- Fundamental
- Price
- CLDI $0.36
- CLRB $0.36
- Analyst Decision
- CLDI Strong Buy
- CLRB Hold
- Analyst Count
- CLDI 1
- CLRB 2
- Target Price
- CLDI $10.00
- CLRB N/A
- AVG Volume (30 Days)
- CLDI 456.3K
- CLRB 34.3M
- Earning Date
- CLDI 05-14-2025
- CLRB 05-13-2025
- Dividend Yield
- CLDI N/A
- CLRB N/A
- EPS Growth
- CLDI N/A
- CLRB N/A
- EPS
- CLDI N/A
- CLRB N/A
- Revenue
- CLDI N/A
- CLRB N/A
- Revenue This Year
- CLDI N/A
- CLRB N/A
- Revenue Next Year
- CLDI N/A
- CLRB N/A
- P/E Ratio
- CLDI N/A
- CLRB N/A
- Revenue Growth
- CLDI N/A
- CLRB N/A
- 52 Week Low
- CLDI $0.34
- CLRB $0.22
- 52 Week High
- CLDI $3.89
- CLRB $3.42
- Technical
- Relative Strength Index (RSI)
- CLDI 34.85
- CLRB 61.13
- Support Level
- CLDI $0.34
- CLRB $0.23
- Resistance Level
- CLDI $0.39
- CLRB $0.69
- Average True Range (ATR)
- CLDI 0.04
- CLRB 0.05
- MACD
- CLDI 0.00
- CLRB 0.02
- Stochastic Oscillator
- CLDI 15.45
- CLRB 26.84
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.